Apollo Commercial Real Estate Finance (ARI) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
6 Feb, 2026Executive summary
Announced acquisition of a $9 billion commercial real estate loan portfolio from ARI, emphasizing alignment with a liability-matched investment strategy and focus on high-quality assets.
Transaction involved robust scrutiny, due diligence, and independent governance oversight, with pricing validated by third-party advisors.
Emphasis on long-term, predictable outcomes for clients, prioritizing downside protection and consistency in investment approach.
Related party transactions
The acquired loan portfolio includes assets where the acquirer has previously partnered with ARI and served as a co-lender in nearly half of the portfolio.
Risk oversight and compliance
Transaction process included independent governance oversight and third-party validation to ensure rigorous risk management.
Latest events from Apollo Commercial Real Estate Finance
- $8.8B loan portfolio, 9.4% yield, and robust Apollo backing drive strong performance.ARI
Investor presentation9 Mar 2026 - Shareholders to vote on $9B asset sale to Athene, revised management fees, and future strategy.ARI
Proxy Filing9 Mar 2026 - Shareholders are asked to approve a $9B commercial loan sale to Athene, offering higher yields.ARI
Proxy Filing20 Feb 2026 - Portfolio sale prompts asset value maximization and strategic review, with shareholder vote pending.ARI
Proxy Filing12 Feb 2026 - 2025 net income was $114M; full loan portfolio sale to Athene at 99.7% of commitments.ARI
Q4 202511 Feb 2026 - Stockholders to vote on $9B asset transfer to Athene, aiming to enhance value and efficiency.ARI
Proxy Filing10 Feb 2026 - Proposed $9B real estate loan portfolio acquisition highlights disciplined, long-term strategy.ARI
Proxy Filing6 Feb 2026 - $9B loan portfolio sale at 99.7% unlocks $1.4B cash, validates book, and enables strategic review.ARI
Status update3 Feb 2026 - Q2 distributable earnings $0.35/share; $90M CECL reserve expected for healthcare loan.ARI
Q2 20242 Feb 2026